Takeda reported that zasocitinib, the TYK2 inhibitor it acquired in a $4 billion deal, met co‑primary and key secondary endpoints in two pivotal Phase 3 trials for plaque psoriasis. The company said more than half of treated patients achieved 'clear or almost clear' skin and will file for regulatory approvals in 2026. Takeda will present detailed data at an upcoming medical meeting and has ongoing studies testing zasocitinib across additional immune‑mediated indications. Reported adverse events included respiratory infections and acne; company statements emphasize a manageable safety profile. Investors and competitors will watch dosing data and head‑to‑head comparisons; the TYK2 class already has an approved agent, and Takeda positions zasocitinib as a differentiated oral alternative to injectable biologics. Success in psoriasis accelerates Takeda’s broader immunology strategy and supports global launch planning next year.